btlines

ACXP Nasdaq Earnings call

Acurx Pharmaceuticals, Inc. (ACXP) · Q2 2026 results

Share price: $1.03 · 2026-11-11

Results Q2 2026 vs Q1 2026 · previous quarter · published 14 Aug 2026 and 12 May 2026

Net loss widened on the previous quarter. Management sounded cautious, in its script and in answers to analysts.

Only a basic analysis is available for this company at the moment.

1 · Numbers

Loss widened

Net income vs Q1 2026

Net income -2.3M vs -1.7M

Net income -2.3M vs -2.2M in Q2 2025 and -1.7M last quarter.

Why The company reported a net loss of $1.7 million or $0.62 per diluted share, which decreased due to lower professional fees and legal costs.

2 · How management spoke

Cautious

Among the least upbeat of all company calls

Answers to analysts: cautious, in line with the script.

Similar to last call.

3 · What stood out

New

The company reported a generally high incidence of difficult infections across various countries.

Valuation

Reverse DCF. Free cash flow from the last full fiscal year, grown for 10 years, discounted back, plus a terminal value. “Implied growth” is the rate the current price assumes.

Valuation unavailable: no OCF/capex (bank, utility, or SEC gap).

Current price

$1.03

close of 2026-11-11

Read between the lines

  1. Fading

    The company reported a net loss of $1.7 million or $0.62 per diluted share, which decreased due to lower professional fees and legal costs.

    Source quote
    “The company reported a net loss of $1.7 million or $0.62 per diluted share for the... The decrease was primarily due to a $0.1 million decrease in professional fees and a $0.1 million decrease in legal costs.”

Tone

How upbeat the language was, compared with other companiesiTone counts positive minus negative finance words, adjusted for length. Executives mostly speak positively, so the labels compare each call with every company's latest call: “typical” is the middle third, “very upbeat” the top tenth, “cautious” the bottom tenth.. Dot: Q2 2026. Ring: Q1 2026.

Prepared remarks Cautious (was cautious)
Answers to analysts Cautious (was cautious)

Script and answers carried a similar tone, so the script's message held up under questioning.

Sentences that drove the tone
“This new partnership builds on the previously reported successful results from the innovative research grant received from the Dutch government in November 2025.”
“The company reported a net loss of $2.3 million or $0.53 per diluted share for the 3 months ended June 30, 2026 that was compared to a net loss of...”

Full figures

USD · ROIC.AI fundamentals (NASDAQ:ACXP, period end 2026-06-30)

Metric Q2 2026period end 2026-06-30 Q1 2026period end 2026-03-31 Change Q2 2025 YoY
Revenue 0 0 0
Operating income -2.3M -1.7M Loss widened -2.3M Loss widened
Net income -2.3M -1.7M Loss widened -2.2M −0.4%
EPS -0.53 -0.62 Loss narrowed -1.89 Loss narrowed
P/E 12-mo loss 12-mo loss — 12-mo loss —

Topics

Most discussed now

  • One of the features of this new ASPIRE trial design is to measure the patients an extraordinary amount of time...
  • Acurx Pharmaceuticals doesn't have to show superiority over vancomycin for the clinical care acute treatment endpoint.
  • Interestingly, whether or not the ASPIRE trial is eventually funded, there's a second pathway to FDA approval under the LPAD...

Faded since Q1 2026

  • Fading Diff starting with an exploratory 20-patient Phase II, look at the data, and then Acurx Pharmaceuticals would do hopefully a, one...
  • Fading There's a Phase III pathway in what Acurx Pharmaceuticals calls acute CDI, which is currently 2 Phase III registration trials that...
  • Fading You can clarify between the Phase III trials.
  • Fading The company reported a net loss of $1.7...

Latest announcements

Official filings, newest first.

Similar companies

Healthcare · Biotechnology
All Healthcare companies →